L3VLUP
ProSign in

BIO · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BIOJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BIO
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterBIOJNJ
Q3 202017 holders, $1.7bn30 holders, $26.2bn
Q4 202013 holders, $2.2bn32 holders, $26.6bn
Q1 202115 holders, $2.2bn31 holders, $25.3bn
Q2 202118 holders, $2.7bn37 holders, $25.6bn
Q3 202116 holders, $3.5bn40 holders, $24.1bn
Q4 202119 holders, $3.3bn33 holders, $25.2bn
Q1 202222 holders, $2.4bn35 holders, $28.2bn
Q2 202215 holders, $1.2bn33 holders, $26.9bn
Q3 202217 holders, $857m36 holders, $25.4bn
Q4 202216 holders, $782m35 holders, $27.6bn
Q1 202311 holders, $833m42 holders, $24.5bn
Q2 202316 holders, $607m38 holders, $25.0bn
Q3 202315 holders, $662m37 holders, $18.9bn
Q4 202311 holders, $534m31 holders, $19.0bn
Q1 20247 holders, $342m32 holders, $19.7bn
Q2 20246 holders, $409m35 holders, $20.4bn
Q3 20249 holders, $708m28 holders, $22.3bn
Q4 202411 holders, $649m37 holders, $20.4bn
Q1 202510 holders, $612m32 holders, $20.5bn
Q2 20258 holders, $780m31 holders, $18.4bn
Q3 20258 holders, $983m32 holders, $23.7bn
Q4 20259 holders, $1.2bn29 holders, $27.8bn
Q1 20268 holders, $1.2bn34 holders, $35.6bn
Q2 20267 holders, $1.1bn33 holders, $39.1bn
BIO

Bio Rad Labs Inc

Holders
10
Reported value
$612m
Buyers
6
Sellers
3

Breadth +3 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
32
Reported value
$20.5bn
Buyers
16
Sellers
15

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BIO (6)

Artisan Partners LP, Caxton Associates LLP, ExodusPoint Capital Management LP, First Eagle Investment Management LLC, Moore Capital Management LP, Southeastern Asset Management Inc

Only JNJ (28)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Verition Fund Management LLC, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →